2023 World Conference on Lung Cancer (Posters)-EP08.02. Moderately Hypofractionated PET/CT-Based Thoracic Radiotherapy in Elderly and Multimorbid Patients with Stage II/III NSCLC

EP08.02. Moderately Hypofractionated PET/CT-Based Thoracic Radiotherapy in Elderly and Multimorbid Patients with Stage II/III NSCLC - PDF(Slides)

Back to course

Pdf Summary

This retrospective study aimed to evaluate the effectiveness and feasibility of PET/CT-based moderately hypofractionated thoracic radiotherapy (hypo-RT) in elderly, multimorbid patients with stage II/III non-small cell lung cancer (NSCLC). The study analyzed 76 patients with primary and recurrent NSCLC, with a median age of 76.7 years. Hypo-RT was delivered in 10-17 fractions, with a total dose of 38.0-56.0 Gy. The median follow-up after radiotherapy was 46.8 months.<br /><br />The results showed that the median progression-free survival (PFS) was 8.0 months, and the median overall survival (OS) was 23.3 months. The median locoregional progression-free survival and distant metastasis-free survival were 14.7 months and 18.8 months, respectively. The 6- and 12-month PFS/OS rates were 61%/84% and 36%/67%. In terms of toxicity, the treatment was well tolerated, with only 3 cases of grade 3 pneumonitis and 1 case of grade 3 esophagitis observed. No grade 3 or higher toxicities were reported.<br /><br />The study demonstrated that PET/CT-based moderately hypofractionated radiotherapy is feasible and effective in elderly, multimorbid patients with stage II/III NSCLC. The survival rates and tolerability of the treatment provide evidence for the efficacy of this treatment strategy. These findings suggest that hypo-RT could be considered as a treatment option for this patient population. Further research and larger studies are needed to confirm these results.

Asset Subtitle

Chukwuka Eze

Meta Tag

Speaker Chukwuka Eze

Topic Local-Regional NSCLC: Multimodality Therapy

Keywords

retrospective study

PET/CT-based moderately hypofractionated thoracic radiotherapy

elderly patients

multimorbid patients

stage II/III non-small cell lung cancer

NSCLC

progression-free survival

overall survival

toxicity

treatment strategy